|
|
Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Methyldopa#Overdosage]] |
| {{Methyldopa}}
| |
| {{CMG}}; {{AE}} {{AK}}
| |
| | |
| ==Overdosage==
| |
| | |
| Acute overdosage may produce acute [[hypotension ]]with other responses attributable to brain and gastrointestinal malfunction (excessive sedation, [[weakness]], [[bradycardia]], [[dizziness]], [[lightheadedness]], [[constipation]], [[distention]], [[flatus]], [[diarrhea]], [[nausea]], [[vomiting]]).
| |
| | |
| In the event of overdosage, symptomatic and supportive measures should be employed. Management includes special attention to cardiac rate and output, blood volume, electrolyte balance, [[paralytic ileus]], urinary function and cerebral activity.
| |
| | |
| [[Sympathomimetic ]]drugs [e.g., [[levarterenol]], [[epinephrine]], ARAMINE* ([[Metaraminol ]]Bitartrate, MSD)] may be indicated.
| |
| | |
| The acute intravenous LD50 of Methyldopate HCl in the mouse is 321 mg/kg.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = METHYLDOPATE HYDROCHLORIDE INJECTION, SOLUTION [AMERICAN REGENT, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f5f25053-a9f3-48b9-a412-078f5ee942fd | publisher = | date = | accessdate = 10 March 2014 }}</ref>
| |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
| | |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |